A New Framework for Assessing Obesity Treatment Success
Evaluating the effectiveness of obesity interventions should incorporate more than just percentage-based weight reduction, according to a recent scientific statement from the Endocrine Society. The document argues that true treatment success requires measuring improvements in metabolic health, body composition, physical capability, and the management of related health conditions.
Published in Endocrine Reviews, the statement was authored by a panel led by Ania M. Jastreboff, MD, PhD, who serves as director of the Yale Obesity Research Center at Yale School of Medicine. The eight-person expert group outlined six key areas requiring attention, including mechanisms of fat regulation, individual differences in obesity and treatment responses, and alternative treatment objectives beyond total body weight reduction percentages.
The current standard for FDA approval of glucagon-like peptide-1 (GLP-1) receptor agonists remains mean percentage weight loss from baseline.
Mir Ali, MD, a bariatric surgeon and medical director at MemorialCare Surgical Weight Loss Center, states that weight loss metrics alone cannot fully determine treatment effectiveness.
Nisha Patel, MD, an obesity medicine specialist with Sutter Health, supports this perspective, emphasizing that clinicians should prioritize measurable health benefits such as improved biomarkers, physical function, and general well-being. She advises moving beyond narrow weight loss targets to evaluate treatment progress more holistically.
The statement rejects the idea of a universal treatment benchmark for all patients. Instead, it advocates for early indicators of therapeutic progress, such as symptom tracking, biochemical data, imaging results, and genetic factors, to guide personalized care strategies. These markers could help tailor medication selection, dosing, and combination therapies while enhancing safety assessments.
The authors propose that obesity management could adopt a model similar to chronic disease treatment, like diabetes, where outcomes are judged by clinically relevant health targets rather than just medication-induced weight changes. They suggest expanding weight loss benchmarks to include thresholds of 25%, 30%, and 35%, beyond the traditional 5%, 10%, 15%, and 20% categories, particularly as newer medications yield more substantial reductions.
Clinical trial data reveals significant weight regain after stopping newer anti-obesity medications, suggesting many patients may require long-term therapy to sustain health outcomes.
Proposed health-focused treatment goals include changes in waist circumference and waist-to-height ratio.